140
Participants
Start Date
April 28, 2017
Primary Completion Date
February 28, 2018
Study Completion Date
June 30, 2018
Liprotamase
oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
porcine PERT
oral, enterically-coated, pig-derived, pancreatic enzyme replacement
Investigator Site 306, Budapest
Investigator Site 307, Budapest
Investigator Site 302, Törökbálint
Investigator Site 304, Mosdós
Investigator Site 106, Hershey
Investigator Site 147, Wilmington
Investigator Site 112, Richmond
Investigator Site 118, Durham
Investigator Site 401, Madrid
Investigator Site 403, Madrid
Investigator Site 402, Málaga
Investigator Site 405, El Palmar
Investigator Site 110, Atlanta
Investigator Site 102, Jacksonville
Investigator Site 117, Altamonte Springs
Investigator Site 130, Miami
Investigator Site 151, West Palm Beach
Investigator Site 134, Jackson
Investigator Site #122, Louisville
Site Investigator #113, Toledo
Investigator Site #103, Cleveland
Investigator Site 404, Valencia
Investigator Site 124, Ann Arbor
Investigator Site 140, Kalamazoo
Investigator Site 148, Iowa City
Investigator Site 109, Glenview
Investigator Site 139, Little Rock
Investigator Site 101, Oklahoma City
Investigator Site 136, Oklahoma City
Investigator Site 111, Dallas
Investigator Site 116, Houston
Investigator Site 150, Denver
Investigator Site 135, Las Vegas
Investigator Site 107, Los Angeles
Investigator Site #123, Long Beach
Investigator Site 143, Orange
Investigator Site 601, Jerusalem
Investigator Site 132, Portland
Investigator Site 901, Kaunas
Investigator Site #902, Vilnius
Investigator Site 203, Karpacz
Site 206, Lodz
Investigator Site 201, Lublin
Investigator Site 205, Lublin
Investigator Site 202, Rabka-Zdrój
Investigator Site 209, Rzeszów
Investigator 204, Sopot
Investigator Site 210, Łomianki
Investigatior Site 701, Southampton
Investigator Site 702, Exeter
Lead Sponsor
Anthera Pharmaceuticals
INDUSTRY